Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881559/0/en/Editas-Medicine-to-Present-Clinical-Data-from-the-RUBY-and-EdiTHAL-Trials-of-Reni-cel-at-the-European-Hematology-Association-2024-Congress-in-June.html

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.